Company Filing History:
1 out of 9 
1 out of 856 
1 out of 1 Years Active: 2017
Title: Soranun Chantarangsu: Innovator and Patent Holder in Bangkok
Introduction:
In the vibrant landscape of Bangkok, Thailand, one innovative mind stands out in the field of pharmaceutical research and risk assessment. Meet Soranun Chantarangsu, a brilliant inventor and expert whose groundbreaking work in predicting the risk of cutaneous adverse drug reactions has earned him recognition within the industry. This article will delve into Soranun's latest patents, career highlights, and collaborations, shedding light on his remarkable contributions to the field.
Latest Patents:
One of Soranun Chantarangsu's notable patents is titled "Risk assessment for cutaneous adverse drug reactions from antiretroviral agent." This groundbreaking invention introduces a method for predicting a patient's risk of developing cutaneous adverse drug reactions to non-nucleoside reverse transcriptase inhibitors (NNRTIs) like nevirapine. Leveraging the HLA-B*3505 allele and the CCHCR1 gene polymorphisms, Soranun's invention offers invaluable insights into drug reactions, enabling more informed decision-making in patient care.
Career Highlights:
Soranun Chantarangsu's expertise spans across leading academic institutions and corporations. He has made significant contributions during his tenure at Mahidol University in Bangkok, where he has contributed to the advancement of pharmaceutical research. Soranun's commitment to pushing the boundaries of knowledge and innovation has not gone unnoticed, and he has also collaborated with the esteemed Riken Corporation, a renowned research institute based in Japan.
Collaborations:
Collaboration is often a catalyst for groundbreaking advancements, and Soranun understands the importance of working alongside fellow experts to propel innovation forward. Throughout his career, he has had the pleasure of collaborating with prominent figures in the field. Noteworthy colleagues include Somnuek Sungkanuparph and Sasisopin Kiertiburanakul, bringing together their collective expertise to tackle challenging problems and pave the way for novel solutions in the pharmaceutical realm.
Conclusion:
Soranun Chantarangsu's presence in the field of pharmaceutical research and risk assessment is truly remarkable. Through his pioneering invention and method for predicting cutaneous adverse drug reactions, he has significantly contributed to enhancing patient care and safety. Soranun's impressive career journey, from his affiliation with Mahidol University to collaborations with esteemed professionals, underscores his dedication to innovation and improving medical outcomes.
For more information on Soranun Chantarangsu, his patents, and his contributions to the field of pharmaceutical research, please visit our website idiyas.com.